Literature DB >> 6128231

Residual effects of repeated doses of 0.5 and 1 mg flunitrazepam.

M Lader, A Melhuish, P Harris.   

Abstract

9 normal subjects were tested on a large battery of tests the morning after a hypnotic dose of flunitrazepam (0.5 mg and 1 mg) and a placebo. Each drug was given for 8 nights and assessments were made 10 and 13 h later on days 1, 4 and 8. Self-ratings of sleep were made every morning. The tests comprised mood and bodily symptom self-ratings, taping rate, visual reaction time, symbol copying and substitution tests, critical flicker fusion threshold, digit span and cancellation test. The EEG was recorded under eyes open and eyes closed conditions and analysed using broad waveband filters. Subjectively, the 0.5 mg dose was associated with increased alertness, contentment and calmness, the 1 mg dose with minimal decrease in alertness and contentment. Sleep onset was accelerated by flunitrazepam initially but effects on quality of sleep were not major due to subject selection. The 1 mg dose occasionally impaired performance on tapping, symbol copying and substitution and critical flicker fusion. The 0.5 mg dose marginally impaired symbol substitution and improved symbol copying. The EEG showed definite dose-related effects which tended to increase over the 8 nights of ingestion of the drug. It is concluded that whereas the 1 mg dose may sometimes be associated with definite residual effects the next day, the 0.5 mg dose possesses positive qualities in producing useful subjective effects the next day without appreciable impairment of psychological performance.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6128231     DOI: 10.1007/bf00545967

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Residual effects of flunitrazepam.

Authors:  A J Bond; M H Lader
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

2.  Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects.

Authors:  H G Boxenbaum; H N Posmanter; T Macasieb; K A Geitner; R E Weinfeld; J D Moore; A Darragh; D A O'Kelly; L Weissman; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1978-08

3.  A controlled long-term study of flunitrazepam, nitrazepam and placebo, with special regard to withdrawal effects.

Authors:  H Hartelius; A K Larsson; M Lepp; U Malm; A Arvidsson; H Dahlström
Journal:  Acta Psychiatr Scand       Date:  1978-07       Impact factor: 6.392

4.  Activity of the hypnotics, flunitrazepam and triazolam, in man.

Authors:  A N Nicholson; B M Stone
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

5.  Pharmacokinetic and clinical observations on prolonged administration of flunitrazepam.

Authors:  E Wickstrøm; R Amrein; P Haefelfinger; D Hartmann
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

6.  A repeated dose comparison of dichloralphenazone, flunitrazepam and amylobarbitone sodium on some aspects of sleep and early morning behaviour in normal subjects.

Authors:  I Hindmarch; A C Parrott; L Arenillas
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

7.  Efficacy of some benzodiazepines for day-time sleep.

Authors:  A N Nicholson; B M Stone; P A Pascoe
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

Review 8.  Flunitrazepam: a review of its pharmacological properties and therapeutic use.

Authors:  M A Mattila; H M Larni
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

  8 in total
  2 in total

1.  Amnesic effects and subjective ratings during repeated dosing of flunitrazepam to healthy volunteers.

Authors:  J Ingum; K M Beylich; J Mørland
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Efficacy and tolerance: comparative studies with brotizolam and flunitrazepam.

Authors:  E Goetzke; P Findeisen; I B Welbers
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.